Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Palatin TechnologiesPTN -2.38%19 3-Year EBITDA Growth Rate is 44.80% as of Mar. 2026, which is 170% above its 10-year median of 16.60. GuruFocus rates PTN with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 1,127 Biotechnology companies, Palatin Technologies ranks better than 81.28% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 44.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 22.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Palatin Technologies was 65.80% per year. The lowest was -18.50% per year. And the median was 16.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Palatin Technologies 3-Year EBITDA Growth Rate Related Terms
PTN vs BIVI, NCEL, KTTA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Palatin Technologies's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Palatin Technologies 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Palatin Technologies's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Palatin Technologies's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 44.80% mean?
Palatin Technologies (PTN) has a 3-Year EBITDA Growth Rate of 44.80% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Palatin Technologies and its competitors. This is 170% above median its historical median of 16.60. According to the industry distribution chart, Palatin Technologies ranks #211 out of 1127 companies in the Biotechnology industry, placing it in the top 18.7%.
Is Palatin Technologies' 3-Year EBITDA Growth Rate too high?
Palatin Technologies' current 3-Year EBITDA Growth Rate of 44.80% is 170% above median its 10-year median of 16.60. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Palatin Technologies' value of 44.80% is 206.8% above this industry median. Based on the distribution chart, Palatin Technologies ranks #211 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Palatin Technologies has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Palatin Technologies' 3-Year EBITDA Growth Rate compare to BIVI and NCEL?
According to the Biotechnology industry distribution chart, Palatin Technologies ranks #211 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Palatin Technologies in the top 19% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.60. Palatin Technologies' value of 44.80% is 206.8% above this benchmark. While the company's 10-year median is 16.60 vs. the industry median of 14.60, Palatin Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Palatin Technologies's current 3-Year EBITDA Growth Rate of 44.80% is 206.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Palatin Technologies and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Palatin Technologies's current 3-Year EBITDA Growth Rate is 44.80%, which is 170% above median its own 10-year median of 16.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Palatin Technologies stock overvalued right now?
Palatin Technologies (PTN) has a current 3-Year EBITDA Growth Rate of 44.80%. The current 3-Year EBITDA Growth Rate is 44.80%, which is 170% above median its 10-year median of 16.60 and 206.8% above the Biotechnology industry median of 14.60. Palatin Technologies' overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Palatin Technologies (PTN), the current 3-Year EBITDA Growth Rate is 44.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. The Company's business is in one operating segment: life science.
19GF Score
Get the complete analysis for PTN
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTN has been successfully added to your 
